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Cancer remains one of the leading causes of deaths worldwide, despite advances in
its treatment and detection. The conventional chemotherapeutic agents used for the
treatment of cancer have non-specific toxicity toward normal body cells that cause
various side effects. Secondly, cancer cells are known to develop chemotherapy
resistance in due course of treatment. Thus, the demand for novel anti-cancer agents is
increasing day by day. Some of the experimental studies have reported the therapeutic
potential of bacteriocins against various types of cancer cell lines. Bacteriocins are
ribosomally-synthesized cationic peptides secreted by almost all groups of bacteria.
Some bacteriocins have shown selective cytotoxicity toward cancer cells as compared to
normal cells. This makes them promising candidates for further investigation and clinical
trials. In this review article, we present the overview of the various cancer cell-specific
cytotoxic bacteriocins, their mode of action and efficacies.
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INTRODUCTION
Cancer is one of the major causes of morbidity and mortality throughout the world among the
non-communicable diseases. In the year 2012, there were an estimated 14.1 million new cases
of cancer and 8.2 million cancer deaths worldwide (Ferlay et al., 2013). Cancer cells are altered
self cells which have escaped normal growth regulating mechanisms. Under normal conditions,
balance is maintained between cell renewal and cell death and the production of new cells is
regulated so that the number of a particular cell type remains constant. But due to environmentally-
induced or inherited genetic mutations, cells stop responding to normal growth control mechanisms
and give rise to clones of cells that expand to considerable size, producing tumor or neoplasm.
Cancer cells show the following six essential alterations in cell physiology: self sufficiency in growth
signals, insensitivity to growth-inhibitory signals, resistance to programmed cell death, limitless
replicative potential, sustained angiogenesis and metastasis (Hanahan and Weinberg, 2011). The
strategies available for the treatment of cancer are chemotherapy, surgery and radiation out of which
chemotherapy is the main choice of treatment. But the conventional chemotherapeutic drugs which
target actively dividing cells are often associated with drug-induced damage to healthy cells and
tissues, as they do not specifically target the cancer cells. Secondly, cancer cells frequently become
resistant to chemotherapy due to various factors such as increased expression of drug detoxifying
enzymes and drug transporters, and due to increased ability to repair DNA defects in cellular
machinery that mediate apoptosis (Raguz and Yagüe, 2008). Therefore, there is an urgent need for
cancer cell-specific targeted therapies that can alone treat cancer or can be used as adjuvants to
lower the therapeutic doses of conventional anticancer drugs.With the growing popularity of peptide
therapeutics, the scientific community has started exploring bacteriocins as novel therapeutic agents
against cancer. The toxic effects of bacteriocins on eukaryotic cells were observed for the first time
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by Farkas-Himsley and Cheung (1976). The effects of bacteriocins
on mammalian cells have been reviewed earlier (Cornut et al.,
2008). In this review, latest studies on the anticancer properties
of bacteriocins have been summarized with particular emphasis
on the studies that have shown selectivity of bacteriocins against
cancer cells as compared to normal cells.
BACTERIOCINS
Bacteriocins are ribosomally-synthesized cationic peptides that
are produced by almost all groups of bacteria. The first bacteriocin
was discovered in the year 1925 by Gratia from Escherichia
coli (Gratia, 1925) and later named as colicin. Since then large
number of bacteriocins have been identified from a diverse group
of bacterial strains. Their physiological functions in bacteria
seems to inhibit the growth of competing microorganisms
in a particular biological niche by killing them (Nes and
Holo, 2000). Most bacteriocins are extremely potent, exhibiting
antimicrobial activity at nanomolar concentrations, as opposed
to the peptide antimicrobials produced by eukaryotic cells,
which normally have 102–103-fold lower activities (Jennsen et al.,
2006). Interestingly, the producer cells are immune to their own
bacteriocins (Cotter et al., 2005). The classification of bacteriocins
has been revised from time to time. The latest classification
arranges bacteriocins into three major classes based on their
structural and physico-chemical properties (Zacharof and Lovitt,
2012).
CLASSIFICATION OF BACTERIOCINS
Class I
Lantibiotics are small (<5 kDa) heat-stable peptides that are
highly post-translationally-modified containing characteristic
polycyclic thioether amino acids such as lanthionine,
methyllanthionine, and the unsaturated amino acids such
as dehydroalanine and 2-aminoisobutyric acid. Lantibiotics are
further classified into two types depending on the difference in
charge.
Type A lantibiotics such as nisin and lacticin 3147 are 2–4 kDa
positively charged, screw-shaped, flexible molecules which causes
pore formation in the cell membrane of the target organism and
thereby leads to depolarization of the cytoplasmic membrane of
the target species.
Type B lantibiotics are 2–3 kDa peptides having either no
net charge or net negative charge. They are globular molecules,
which interfere with cellular enzymatic reactions such as cell wall
synthesis. Mersacidin secreted by Bacillus spp. is an example of
this type (Sahl and Bierbaum, 1998).
Class II
Class II bacteriocins are small (<10 kDa) heat stable, non-
lanthionine containing peptides that are not post-translationally
modified beyond the removal of a leader peptide and the
formation of a conserved N-terminal disulfide bridge. They have
amphiphilic helical structure, which allows them to insert into the
membrane of the target cell, leading to depolarisation and death.
Subclass IIa bacteriocins such as, pediocin PA-1 and sakacin A,
are monomeric and possess an N-terminal consensus sequence
Tyr-Gly-Asn-Gly-Val-Xaa-Cys. They are active particularly
against Listeria monocytogenes. Subclass IIb bacteriocins
include lactacin F and lactococcin G. They are two-component
bacteriocins, in which two separate peptides work synergistically
to generate antimicrobial effect. Cotter et al. (2005) suggested
the third subclass IIc that contains circular bacteriocins such as
gassericin A, circularin A, and carnocyclin A. These peptides
carry two transmembrane segments that facilitate pore formation
in the target cells (Kawai et al., 2004). However, others have
suggested considering circular bacteriocins as a separate class
(Belkum et al., 2011).
Class III
Class III bacteriocins are high molecular weight (>30 kDa) heat
labile proteins. Some of the colicins, megacins (from Bacillus
megaterium), klebicin (from Klebsiella pneumonia), helveticin I
(from L. helveticus), and enterolysin (from E. faecalis) are the
members of this group.
SELECTIVITY OF BACTERIOCINS
TOWARD CANCER CELLS
Some of the bacteriocins (Table 1) as reviewed in the following
sections have shown selective action toward cancer cells. Although
the exact mechanism of the cancer cell specificity has not
been studied but the various factors that could account for the
selective action could be explained based on the generalized cell
surface variations of cancer cells from the normal cells. The
bilayered phospholipid membrane of normal mammalian cells
is asymmetric with respect to the distribution of phospholipids
on the inner and outer surface. The outer surface is made up
of neutral choline-containing zwitterionic phospholipids such
as sphingomyelin and phosphatidylcholine, whereas the inner
surface has aminophospholipids such as phosphatidylserine and
phosphatidylethanolamine. However, in cancer cells there is loss
in asymmetry with respect to phospholipid types. Cancer cell
membrane is known to carry a predominantly negative charge due
to high levels of the anionic phosphatidylserine, O-glycosylated
mucins, sialylated gangliosides, and heparin sulfates (Utsugi et al.,
1991; Schweizer, 2009; Riedl et al., 2011). Bacteriocins are cationic
peptides by nature and thus they preferentially bind to negatively-
charged cell membrane of cancer cells as compared to normal cell
membranes which are neutral in charge (Dobrzyńska et al., 2005;
Hoskin and Ramamoorthy, 2008). Secondly, the selective binding
of bacteriocins to cancer cells can be explained due to differences
in the membrane fluidity of cancer cells. Cancer cells have higher
membrane fluidity as compared to normal cells and this facilitates
easy membrane destabilization (Sok et al., 1999). Lastly, the
membranes of cancer cells contain a significantly higher number
of microvilli compared to normal cells that increases the surface
area of cancer cells (Chaudhary and Munshi, 1995) which results
in the binding of more number of antimicrobial peptides to the
cancer cell membrane as compared to normal cells (Chan et al.,
1998a,b).
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TABLE 1 | The bacteriocins having anticancer activities against various cancer cell lines.
Bacteriocin Producer organism Class Size (kDa) Cancer cell lines References
Colicin E3 E. coli III 9.8 P388, HeLa, HS913T Fuska et al. (1978); Smarda et al.
(1978)
Colicin A E. coli III >20 HS913T, SKUT-1, BT474, ZR75, SKBR3, MRC5 Chumchalova and Smarda (2003)
Colicin E1 E. coli III 57 MCF7, HS913T Chumchalova and Smarda (2003)
Microcin E492 K. pneumoniae IIa 7.9 Hela, Jurkat, RJ2.25 Hetz et al. (2002)
Pediocin PA-1 P. acidilactici PAC1.0 IIa 3.5 A-549, DLD-1 Beaulieu (2004)
Pediocin K2a2-3 P. acidilactici K2a2-3 IIa 4.6 HT2a, HeLa Villarante et al. (2011)
Pediocin CP2 P. acidilactici IIa HeLa, MCF7, Sp2/0-Ag 14, HepG2 Kumar et al. (2012)
Pyocin S2 P. aeruginosa 42A III 74 HepG2, Im9 HeLa, AS-II, mKS-A TU-7 Abdi-Ali et al. (2004); Watanabe
and Saito (1980)
Nisin L. lactis I 3.5 MCF7, HepG2 Paiva et al. (2011)
Bovicin HC5 S. bovis HC5 I 2.4 MCF7, HepG2 Paiva et al. (2011)
Smegmatocin M. smegmatis 14468 III 75 HeLa AS-II, HGC-27 mKS-A TU-7 Saito et al. (1979); Saito and
Watanabe (1979, 1981)
Plantaricin A L. plantarum C11 II 2.4 Jurkat, GH4, Reh, Jurkat, PC12, N2A, GH4 Zhao et al. (2006); Sand et al.
(2007); Sand et al. (2010); Sand
et al. (2013)
COLICINS
Colicins are plasmid-encoded high molecular weight (>20 kDa)
antimicrobial peptides secreted by E. coli and other related
Enterobacteriaceae. They are active against E. coli strains and other
closely related bacteria, such as Salmonella (Braun et al., 1994).
Gratia in 1925 identified the first colicin, a heat labile product
present in cultures of E. coli V. Gratia and Fredericq coined the
term colicin in the year 1946, and demonstrated the proteinaceous
nature and the activity spectra of colicins (Gratia and Fredericq,
1946). Thirty different types of colicins have been identified that
are differentiated according to their killing activity and the mode
of action (Smarda and Smajs, 1998; Lakey and Slatin, 2001).
Colicin production by bacteria occurs principally during times
of stress like nutrient or oxygen depletion and therefore are SOS
regulated (Smarda and Smajs, 1998).
The mechanism of antimicrobial killing has been extensively
studied in colicins and it has been shown that it kill target bacterial
cell in three steps—cell binding, membrane translocation and
cell death. The three different domains in the colicin perform
these steps: The T (translocation) domain is N-terminally located,
the R (receptor binding) domain is in the central region and
the C (cytotoxic) domain is located at C-terminus. Colicins bind
to the outer membrane proteins on target bacterial cells (James
et al., 1996). Once bound to outer membrane, colicin enter cell
by interacting with Tol or Ton complex of periplasmic proteins
(Imajoh et al., 1982) and kill the sensitive target strain by one of
the mechanisms- pore formation (colicins A, B, E1, Ia, Ib, K, L, N,
U, 5, and 10), non-specific DNAse activity (colicins E2, E7, E8, and
E9), or inhibition of protein biosynthesis by cleaving 16S rRNA
or tRNAs (colicins E3, E4, E6, E5, and D) (Bowman et al., 1971;
Cramer et al., 1990; Smarda and Smajs, 1998; Tomita et al., 2000;
Lakey and Slatin, 2001).
Colicins are known to have anticancer activities against a
variety of human tumor cell lines in vitro such as breast cancer,
colon cancer, bone cancer and uteri cell line HeLa. Chumchalova
and Smarda (2003) studied the inhibitory effects of four pure
colicins—A, E1, U, and E3 on 11 human tumor cell lines with
defined mutations of suppressor gene p53 and on one normal
human fibroblast cell line MRC by MTT (tetrazolium bromide)
assay. The effect of colicins on cell cycle was also studied. It was
observed that colicin E1 and A had inhibitory effects on most
of the cell lines. Colicin E1 showed 17–40% inhibition of all 11
cancerous cell lines with small differences among individual cell
lines. The fibrosarcoma HS913T was most sensitive to colicin A,
E1 and U showing 50% inhibition with colicin E1 treatment. The
fibroblastsMRC5was less sensitive to E1 than tumor cells. Colicin
A had strong inhibitory effects varying from 16 to 56% inhibition
of tumor cell lines but it also caused 36% inhibition of normal cell
line MRC5. Breast carcinoma cell lines; BT474, ZR75, and SKBR3
were quite resistant to all tested bacteriocins and the inhibition
ranged from 15 to 25%. Colicin E3 had no significant inhibitory
effect against any cell lines tested.
Further, they studied colicins A-, E1-, and U–mediated cell
cycle alterations in five selected cell lines (human breast cancer
cell lines MCF7 and MDA-MB-231, Osteosarcoma cell line HOS,
HS913T, andMRC5). Colicin A resulted in cell cycle alterations in
both cancer cell line HST913T and normal cells MRC5; whereas,
Colicin E1 treatment altered the cell cycle only in MCF7 line
(number of cells in G1 phase got elevated by 26%). Colicins U and
E3 did not show any significant change in cell cycle.
Furthermore, Colicin A resulted in an increase in proportion
of cells undergoing apoptosis by 7–28% in all cell lines except
HS913T. Apoptosis in MCF7 line was increased by 58% and in
HS913T line by 14% after treatment with colicin E1. In a separate
report, Colicin E3 exhibited 100% killing effect on human uteri
carcinoma cell line, HeLa at the lethal units of 105 (Smarda
et al., 1978). Colicin E3 also showed time- and dose-dependent
inhibitory effect on the proliferation of murine leukemia cells
P388 (Fuska et al., 1978). The anticancer activity was observed
only against the carcinoma cells at the doses that do not affect
the normal cell line. In another study, three different murine
lymphoma cell lines showed decrease in viability by 40–58% after
treatment with colicin A and E2 (Smarda and Oravec, 1989).
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Again, the effect of colicins on tumor cells was highly specific.
Colicins E1 and E3 were found to be cytotoxic for oncogene v-
myb-transformed chicken monoblasts. However, colicin E3 did
not cause any alterations in cell cycle which may indicate that it
kill cells by necrosis rather than apoptosis (Smarda et al., 2001).
In vivo mice studies have also shown the protective anticancer
effects of colicins. Direct injections of colicin E3 into the
subcutaneous nodes of solid HK-adenocarcinoma showed 61%
decrease in mean mass of tumor in mice (Cursino et al., 2002).
Treatment with colicin A showed 43% prolonged survival of
mice with transplanted LP-2 plasmacytoma (Chumchalova and
Smarda, 2003).
The mechanism of cytotoxicity of colicins is not well
understood. Few reports have shown that colicin E3 cleaves the
18S rRNA of the isolated eukaryotic ribosomes but whether
rRNase domain of E3 is able to enter eukaryotic cells to allow it
to attack ribosome is not known (Turnowsky et al., 1973; Suzuki,
1978). RNase and pore forming colicins kill tumor cells by
generating pores in the plasma membrane. These pores activate
apoptosis and many cells did not cross G1 phase of their cell
cycle as shown in the previously referred study (Chumchalova
and Smarda, 2003). It was also shown that colicin E3-treated cells
had changes in their plasma membrane that lead to apoptosis
(Chumchalova and Smarda, 2003).
MICROCINS
Microcins are small sized (<10 kDa) bacteriocins secreted
by enterobacteria (mostly E. coli) apart from colicins that
are large sized proteins. They are secreted under conditions
of nutrient depletion and exert potent antibacterial activity
against closely related species. Fourteen microcins have been
reported till date, out of which only seven have been isolated
and characterized. The typical gene clusters encoding the
microcin precursor, the self-immunity factor, post-translational
modification enzymes and the secretion factor are located either
on plasmids or on the chromosome. Class I microcins have
the lowest molecular masses, ranging from 1 to 3 kDa, and
display extensive post-translational modifications of their peptide
backbone. Examples are B17, C7/C51J 25. The genes for all
the three class I microcins are located on plasmids. Class II
microcins are higher molecular mass microcins than class I
microcins (4.9–8.9 kDa). Class II is further subdivided into
two subclasses: class IIa, some of which contain disulfide bonds
but no further post-translational modification (L, V, 24), and
class IIb are linear microcins that may carry a C-terminal
post-translational modification (E492, M and presumably H47
and I47).
Microcin E492 (M-E492) is low molecular mass (7887 Da)
bacteriocin which is secreted by Klebsiella pneumoniae RYC492.
It is known to have potent antimicrobial activity against number
of pathogenic bacteria such as E. coli, Klebsiella, Salmonella,
Citrobacter, and Enterobacter (Lorenzo, 1984). It acts by forming
pores in the cell membrane of target cell and thereby disrupting
the cellmembrane potential (Lorenzo, 1984; Lorenzo and Pugsley,
1985; Lagos et al., 1993). M-E492 has modular structure and
each module has specific function. The N- terminal module is
responsible for its antibacterial activity andC- terminal is required
for receptor recognition.
The toxic effect of M-E492 has been reported against
various human malignant cell lines such as HeLa (human
cervical adenocarcinoma), Jurkat (T cell derived from acute
T cell leukemia), RJ2.25 (a variant of Burkitt’s lymphoma),
and colorectal carcinoma cells. On the other hand, no effect
was observed against normal bone marrow cells, splenocytes,
KG-1, human tonsil cells and non-tumor macrophage derived
cells (Hetz et al., 2002). The Jurkat was most sensitive of all
the three cancerous cell lines with 96% loss in viability after
24 h of incubation with 14 mg/ml of M-E492. Further, it was
shown that M-E492 caused apoptosis of cancerous cells at low
concentrations (10 mg/ml) and necrosis at higher concentrations
(20 mg/ml). Apoptosis is a preferred mode of cell death over
necrosis as it is not known to induce inflammatory response.
The prominent biochemical andmorphological changes observed
during apoptosis of cancer cells caused by M-E492 includes
cell shrinkage, DNA fragmentation and extracellular exposure of
phosphatidylserine. Also, apoptosis due toM-E492 was associated
with the activation of caspases, loss of mitochondrial membrane
potential, and release of calcium ions from intracellular stores
(Hetz et al., 2002).
The induction of apoptosis of HeLa cells was 100 times better
when the cells were incubated with M-E492 producer strain E.
coli VSC257pJEM15 carrying the plasmid for MccE492 rather
than the purified protein (Hetz et al., 2002). Thus, this shows an
alternative way to deliver M-E492, provided the bacterial strain
is non-toxic, non-immunogenic to the host, is able to replicate
only in the tumor, and could be completely eliminated from the
host. Interestingly, a study reported that the probiotic E. coliNissle
1917 selectively colonizes tumors (and not healthy organs) when
systemically administered to mice (Brader et al., 2008). E. coli
Nissle 1917 has been used safely as probiotics under the name
Mutaflor®, in humans for almost a century for the treatment
of several intestinal disorders (Rembacken et al., 1999; Kruis,
2004). This strain produces both microcin M and microcin H47,
however, the anticancer properties of these microcins are not
known. Thus, it will interesting to test E. coli Nissle 1917 as
delivery vehicle for the delivery of M-E492 in the tumor-bearing
animal models.
The in vivo effects of M-E492 on human tumor cells were
studied in a preclinical model in which human colorectal
carcinoma xenografts were grown in nude mice. Preliminary
results showed that M-E492 fibrils administered had antitumoral
activity (Lagos et al., 2009). M-E492 is known to forms amyloid-
like fibrils in vitro. Fibril formation is associated with the loss of
antibacterial activity, however, it retains its ability to inhibit cancer
cell lines. fibrils may be used as a depot for the sustained release
of the peptides with biological activity (Turnowsky et al., 1973).
PYOCINS
Pyocins are produced by more than 90% of Pseudomonas
aeruginosa strains and each strain may synthesize several
pyocins (Michel-Briand and Baysse, 2002). A bacteriocin
from P. aeruginosa 10 was isolated for the first time by
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Jacob (1954) after treatment of the cells with ultraviolet
irradiation (mutagen). The pyocin genes are located on the
P. aeruginosa chromosome and their activities are inducible
by mutagenic agents such as UV radiations and mitomycin C
(Kageyama and Egami, 1962). Three types of pyocins are known.
(i) R-type pyocins resemble non-flexible and contractile tails of
bacteriophages. All R-type pyocins are nuclease- and protease-
resistant. They cause depolarisation of the cytoplasmicmembrane
with pore formation in target bacteria. (ii) F-type pyocins also
resemble phage tails, but with a flexible and non-contractile
rod-like structure. (iii) S-type pyocins are colicin-like, protease-
sensitive bacteriocins. They are made of two components. The
large component carries the killing activity (DNase activity for
pyocins S1, S2, S3, AP41; tRNase for pyocin S4; channel-forming
activity for pyocin S5).
Initially it was shown that partially purified pyocin obtained
from P. aeruginosa under specific growth conditions, contain
proteins that are lethal to L6OT mice fibroblast cell line (Farkas-
Himsley and Cheung, 1976). Subsequently, Abdi-Ali et al.
(2004) reported the cytotoxic effect of purified pyocin S2 and
partially purified pyocin isolated from P. aeruginosa 42A on
tumor cell lines –HepG2 (Human hepatocellular carcinoma) and
Im9 (Human immunoglobulin-secreting cell line derived from
multiple myeloma) and one normal cell line HFFF (Human fetal
foreskin fibroblast). A dose-dependent inhibitory effect of Pyocin
S2 was observed on tumor cell lines, whereas both pyocin S2
and partially purified protein was totally non-toxic to normal cell
line HFFF. The cell line Im9 was more sensitive as compared to
HepG2 and maximum growth inhibition of 80% was observed at
maximum pyocin concentration of 50 U/ml after 5 days of cell
incubation at 37°C and 5% carbon-dioxide.
The cytotoxicity of pyocin S2 was also observed by Watanabe
and Saito (1980) against cancerous cell lines (HeLa, AS-II
derived from embryonal carcinoma of ovary, simian virus-
40 transformed mouse kidney cell line mKS-A TU-7) and
normal mice cells (BALB/3T3). However, it had no cytotoxicity
against some of the cancerous (HCG-27) and normal cells
(rat kidney and human lung cells). The cytotoxicity was
completely abolished by the addition of pyocin-sensitive cell
membrane preparations, but not by adding cell membranes
of pyocin-resistant cell. The periodate and neuraminidase
treatment of pyocin-sensitive cell membrane preparations did not
abolished the cytotoxicity of pyocin S2. Further, various sugars
(-galactose, N-acetyl -galactosamine and N-acetyl neuraminic
acid) neutralized the cytotoxicity-inhibitory activities of pyocin-
sensitive cell membrane preparations, thereby hinting at the role
of these sugar moieties on the cell membrane in their interaction
with pyocin S2.
PEDIOCIN
Pediocins are small (>5 kDa), class IIa bacteriocins that
are plasmid-encoded and produced by members of genera
Pediococcus (Papagianni, 2003). They are thermostable peptides,
active over a wide pH range, but sensitive to the action of
many proteolytic enzymes like papain, pepsin, protease, trypsin
and a-chymotrypsin (Kumar et al., 2011). Their N-terminal
region contains the conserved Y-G-N-G-V/L “pediocin box”
motif and two conserved cysteine residues that are joined by
a disulfide bridge that forms a three-stranded antiparallel beta-
sheet. The cationic N-terminal beta-sheet domain mediates
binding of the class IIa bacteriocin to the target cell membrane;
whereas the C-terminal region forms hairpin that penetrates into
the hydrophobic region of the target cell membrane, thereby
mediating leakage through the membrane (Fimland et al., 2005;
Drider et al., 2006). There are various types of pediocins, such
as pediocin L50, AcH, AcM, CP-2, F, K1, L, L-50, SJ-1, and
manymore. The types of pediocins, their characteristic properties,
producing strains and their antimicrobial spectrum has already
been reviewed (Papagianni and Anastasiadou, 2009; Kumar et al.,
2011; Lohans and Vederas, 2012).
Pediocin PA-1 produced by P. acidilactici PAC1.0 and the
recombinant pediocin cloned in Pichia pastoris inhibited the
growth of cell lines A-549, a human lung carcinoma and DLD-
1, human colon adenocarcinoma. Native pediocin PA-1 showed
cytotoxic effect at very low concentrations of 1.6 mM whereas
recombinant pediocin was ineffective at this concentration
(Beaulieu, 2004). Another pediocin similar to PA-1 isolated from
P. acidilactici K2a2-3, having molecular weight of 4.6 kDa was
reported to have cytotoxic activities against HT29, a human
colon adenocarcinoma and HeLa cell lines (Villarante et al.,
2011). Using MTT assay, the study showed the inhibitory
effect of dialyzed (800 AU/ml) and undialyzed (1600 AU/ml)
bacteriocin fraction on the growth of cancer cell lines—HeLa
and HT29. The percentage inhibition of HT29 observed with
dialyzed and undialyzed fractions of bacteriocin were 53.7  7.0,
55.0  4.8, respectively. HeLa cell line was inhibited significantly
more by undialyzed fraction (52.3  6.0%) as compared to
dialyzed fraction (15.6  4.0%). In this study the specificity
of the bacteriocin toward cancer cell lines was not tested. The
mechanism of cytotoxicity was also not studied.
In yet another report, pediocin CP2 produced by P. acidilactici
CP2 MTCC5101 and its recombinant version, synthetic fusion
protein cloned in E. coli BL21(DE3)-pedA, were tested for their
cytotoxic effects against various human cancer cell lines such as
HepG2, HeLa and MCF7 (a mammary gland adenocarcinoma).
The inhibition appeared to be dose-dependent as more inhibition
was observed at 25 mg/ml than at 1 mg/ml. When treated with
25 mg/ml rec-pediocin and native pediocin CP2, MCF-7 cell lines
retained the percentage viabilities of 2.13 and 10.74, respectively;
whereas, HepG2 cell lines retained 5.52 and 1.23% viabilities,
respectively (Kumar et al., 2012). HeLa cells appeared to be
comparatively resistant to the effects of both rec-pediocin and
native pediocin. The authors also reported that rec-pediocin
caused apoptosis of the cancer cells after 48 h of incubation as
studied by DNA fragmentation method.
NISIN
Nisin is a low molecular weight pentacyclic antibacterial peptide
of 34 amino acid residue produced by Lactococcus lactis
subspecies lactis (Hansen and Liu, 1990). This bacteriocin
belongs to the class lantibiotics. It consists of uncommon
amino acids- lanthinone, methyllanthionine, didehydroalanine
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and didehydro-aminobutyric acid, introduced during post-
translational modifications of protein (Klaenhammer et al., 1993).
Nisin is a heat-stable bacteriocin (Jack et al., 1994) and has
antimicrobial activity at nanomolar concentrations against wide
range of Gram-positive bacteria and even against other lactic
acid bacteria but no significant activity is reported against Gram-
negative bacteria. Due to its non-toxicity in animals,WorldHealth
Organization, 1969 and Food and Drug administration (FDA) in
1988 (FDA, 1988) approved the consumption of nisin by humans
as safe. It interacts with lipid II (Wiedemann et al., 2001), a
membrane-bound precursor involved in cell-wall biosynthesis
and generates pores in the target bacterial cells (Ruhr and Sahl,
1985; Sahl et al., 1987).
Paiva et al. (2012) demonstrated the cytotoxic effect of nisin to
MCF-7 (human breast adenocarcinoma cell line) andHepG2. The
IC50 (the concentration at which half of the cells are inhibited)
values for both these cell lines were 105.46 and 112.25 mM,
respectively. At the highest concentration tested, i.e., 140 mM,
the cell viabilities of both the cell lines were found to be less
than 20%. The reduction in cell viability of cancer cell lines
was shown to be dose-dependent and at concentrations above
IC50, cell shrinkage, vacuolization of cytoplasm, condensation
and lateralization of nucleus was observed under the optical
microscope ultimately leading to detachment of cells. The normal
cell line was not used a controls to compare the cancer cell-
specific activity. In yet another study (Begde et al., 2011), the
IC50 cytotoxicity of nisin against Jurkat cell line was found to be
225mM; however, the same concentrations were known to inhibit
the normal human lymphocytes as well. However, no apoptosis of
both the cancer cell line and normal cell lines were observed at the
cytotoxic concentrations as investigated by DNA fragmentation
assay (Begde et al., 2011). Maher and McClean (2006) reported
the cytotoxicity of nisin against two human adenocarcinoma of
colon and colorectum, HT29 and Caco-2 cell lines, and the IC50
values reported were 89.9 mM and 115 mM, respectively.
Joo et al. (2012) showed cytotoxicity of nisin in head and neck
squamous cell carcinoma (HNSCC) both in vitro and in vivo.
ThreeHNSCC cell linesUM-SCC-17B,UM-SCC-14A andHSC-3
were treated with nisin at different doses and primary human oral
keratinocyteswere used as control. Nisin at the doses ranging from
20 to 80 mg/ml showed significant increased apoptosis against all
the three cancer cell lines as measured by DNA fragmentation
and reduced cell proliferation as compared to the control oral
keratinocytes. This cytotoxicity was conferred by apoptosis, cell
cycle arrest and reduction in cell proliferation. Nisin was shown to
cause apoptosis by alteration in calcium influx and cell cycle arrest
in G2 phase as significantly higher calcium influx was observed in
case of HNSCC cell lines as compared to primary keratinocytes.
Further they employed Affymetrix gene array to study the
effects of nisin on 39,000 genes. They identified that CHAC1,
cation transport regulator and apoptosis mediator was fourfold
upregulated in nisin-treated HNSCC cells. Furthermore, the in
vivo effects of nisin was tested in oral xenograft mouse model.
Nisin at the daily dose of 200 mg/kg for 3 weeks significantly
reduced the tumor volumes as compared to controls.
In a very recent report (Kamarajan et al., 2015), the natural
variants of nisin, nisin A and nisin Z were tested for cytotoxic
effects on HNSCC cells both in vitro and in vivo in mice model.
Both the variants of nisin showed significant dose-dependent
decrease in the cell proliferation of the three cell lines (HSC-3,
UM-SCC-17B, and UM-SCC-14A) at the doses ranging from 100
to 800 mg/ml, and similar dose-dependent effects were observed
on the increase in number of apoptotic cells for two of the cell
lines (HSC-3 and UM-SCC-17B). Apoptosis was determined by
staining with annexin V and flow cytometry and by imaging cells
with digital microscope after staining the cells with fluorescent
dyes. Also nisin A and Z were tested for their efficacies in treating
the tumors, established in the floor of mouth by subcutaneously
injecting UM-SCC-17B cells. Oral gavage of nisin A and Z, at the
dose of 800 mg/kg body weight per day for 3 weeks significantly
reduced the mean mass of tumors by 3- and 17-fold respectively
as compared to the control group gavaged with water only.
Preet et al. (2015) studied the synergistic effect of nisin along
with doxorubicin on dimethylbenz (a) anthracene-induced skin
carcinogenesis in mice. They showed that nisin and doxorubicin
alone reduced the mean tumor volumes by 14 and 51.3%,
respectively after 4 weeks of treatment. Whereas the combination
of nisin-doxorubicin reduced the tumor volume by 66.82% as
compared to the untreated group. In nisin-doxorubicin treated
group, cells showed chromatin condensation and marginalization
of nuclear material which might be due to apoptosis in tumor
tissues. From this study they concluded that nisin has ability to
increase the potential of chemotherapeutic drug, doxorubicin.
PLANTARICIN A
Plantaricin A (plnA), produced by Lactobacillus plantarum C11
is a 2.4 kDa class II antimicrobial bacteriocin having pheromone-
like activity. It exists in three variable forms: a 26 residue peptide
and two N-terminally truncated forms containing 23 and 22
residues. All the three variants are derived from 48-residue
precursor encoded by plnA gene (Diep et al., 1996). It possesses
antimicrobial activity against closely related species of lactic acid
bacteria in the pH range 4.0–6.5 (Daeschel et al., 1990). The
amphiphilic nature of plnA results in its oligomerization into the
cell membrane of the target bacteria and thereby forming pores
(Nissen-Meyer et al., 1993).
Zhao et al. (2006) reported the dose- and temperature-
dependent cytotoxicity of artificially synthesized plnA against
human T cell leukemia cell line, Jurkat, in vitro. The cell viability
decreased by 75% after treatment with 25 mM plnA at 20°C;
whereas at 37°C the cell viability was reduced by 55%. The
mode of killing appeared to be apoptosis along with necrosis
as observed microscopically by fragmentation of cell nuclei and
plasma membrane of cancer cells. The intracellular concentration
of caspase-3 in jurkat cell line was also increased upon treatment
with plnA. Further the effect of lipid composition of liposomes
on the interaction of plnA with liposomal membranes was
studied (Zhao et al., 2006). PlnA readily permeabilized the
liposomes containing negatively charged phospholipids as shown
by leakage of fluorescent dye carboxyfluorescein, and secondly it
was shown that plnA forms amyloid like fibrils upon binding with
negatively charged phospholipids, such as phosphatidylserine
(Zhao et al., 2004, 2006). Thus, the negatively charged lipids of
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target cell membrane might promote the association of plnA and
concentrate it on the target cell membrane. The study concluded
that the concentrating effect of the phospholipids was responsible
for effectiveness of these peptides at nanomolar concentrations
and fibril formation could be important for its cytotoxicity. A
significant increase in the exposure of phosphatidylserine on
the surface of various types of cancer cells have been reported
earlier (Riedl et al., 2011), that might be responsible for enhanced
interaction of plnA with tumor cells.
In another report (Sand et al., 2007), the effect of artificially-
synthesized plnA on the permeabilization of normal as well as
cancerous rat anterior pituitary cells (GH4 cell line) was studied
by using whole-cell patch-clamp recordings of the membrane
potential and also by microfluorimetry that measured cytosolic
Ca2+ concentration by using Ca2+-sensitive fluorochrome fura-
2. PlnA in a dose-dependent manner differentially permeabilized
GH4 cell line whereas normal cells were resistant. GH4 cells were
exposed to different concentrations of plnA by using pressure
ejection. At 10 mM plnA concentration, 12 cells out of 25 got
permeabilized; at 100 mM, 27 out of 29 were permeabilized
within few seconds of exposure and at 1 mM concentration
all cells were instantly permeabilized; whereas, plnA had no
permeabilizing effect on normal cells even at the concentration
of 1 mM. However, in a separate study, Sand et al. (2010) did
not find any significant differential effect of plnA on normal
and cancerous cell lines. The cytotoxicity of plnA was studied
on normal human B and T cells, Reh cells (human B cell
leukemia cell line), Jurkat cells, normal rat cortical neurons and
glial cells, PC12 (rat adrenal chromaffin tumor), and murine
N2A cell lines (spinal cord tumor cell line). PlnA at 20 mM
concentration caused 100% cell death of cancerous cell lines,
Reh and Jurkat; whereas 100% cell death of normal cell lines
occurred at 40 mM concentration. The difference in the dose for
the cell death of cancer and normal cells was non-significant for
selectively targeting cancer cells under physiological conditions.
Thus, structural modifications of plnA should be tested for their
selectivity to cancer cells. But, rational modification warrants the
knowledge of the molecular mechanism of cytotoxicity of plnA.
Thus, to identify the surface molecules on the eukaryotic cells
critical for the interaction of plnA with eukaryotic cell, further
studies were done (Sand et al., 2013). The group reported that the
membrane permeabilizing effect of plnA in case of eukaryotic cell
membranes is dependent on the negative surface charge conferred
by membrane glycosylated proteins. The permeabilizing effect
of plnA was observed at the concentration of 100 mM in GH4
cells by using patch clamp membrane conductance recordings
and microfluorometric techniques. However, the permeabilizing
effect of plnA was drastically reduced on neutralizing the
negative surface charge of cells by the addition of Ca2+ or
poly-D-lysine to GH4 cells. Further, to test the role of surface
glycoproteins in cell membrane permeabilization, GH4 cell
patches were treated with trypsin for 1 min and then studied
the membrane permeabilization. Trypsin-treated GH4 cells were
resistant to plnA at 100 mM concentration. Similarly, removal
of carbohydrate residues from glycosylated membrane proteins
by exposing the cells to a mixture of enzymes—PNGase F,
chondroitinase ABC and heparinase I, II, III made the cells
resistant to plnA-induced permeabilization. Thus, this study
shows the role of glycosylated membrane proteins in plnA-
induced membrane permeabilization. The contrasting results
were obtained in another study, wherein the effects of bacteriocins
pln C, nisin A and pediocin-1/AcH were tested for their
cytotoxicities against cancer cell lines HeLa and HT29 (Martín
et al., 2015). All the three bacteriocins tested at concentrations
1 and 10 mg had no cytotoxic effects against the cell lines HT29
and HeLa; however, enzymatic treatment (chondroitinase ABC
and heparinase I, II, III) of the cell lines prior to bacteriocin
addition resulted in loss in cell viabilities by almost 70% as
shown by trypan blue assay. Thus, the study concluded that
glycosaminoglycans on the eukaryotic cell surface are negatively
charged that binds to the positively charged bacteriocins and
neutralize them. However, removal of the glycosaminoglycans
resulted in making the cell lines susceptible to the cytotoxic effect
of the bacteriocins. PlnC is a 3.5 kDa lantibiotic produced by L.
plantarum LL441 (Turner et al., 1999). The study used very low
concentration of plnC, i.e., 10 mg that amounts to 2.86  10 6
mM as compared to the previous studies in which 100 mM
plnA was used. The high concentrations of the bacteriocins may
have entirely altered cytotoxic effects on the cell lines. Also
cell-specific cytotoxic effects of bacteriocins is already known.
Thus, difference in the bacteriocin concentration and eukaryotic
cell types used in both the experiments may to some extent
explain the contrasting results obtained. Nevertheless the role
of glycosaminoglycans in interacting with bacteriocins remains
unresolved.
BOVICIN
Bovicin is a lantibiotic produced by Streptococcus bovis HC5
having molecular weight of 2.4 kDa. It is stable to autoclaving
and low pH and is structurally and functionally similar to nisin. It
has broad-spectrum antimicrobial activity against closely related
S. bovis strains as well as various other Gram-positive and Gram-
negative bacteria but do not inhibit E. coli K-12. The activity
is resistant to proteinase K and a-chymotrypsin but sensitive to
pronase E and trypsin. The antimicrobial activity is due to pore
formation in cell membrane and inducing potassium efflux in the
target cells (Mantovani et al., 2002). Paiva et al. (2012) reported the
cytotoxic activity of bovicin HC5 in vitro against human cell lines-
MCF7 and HepG2. The IC50 values of bovicin for both these cell
lines were 279.39 mM and 289.3 mM, respectively. At the highest
concentration tested, i.e., 350 mM, the cell viabilities of both the
cell lines were found to be less than 20%.
SMEGMATOCIN
Smegmatocin 14468 is a 75 kDa bacteriocin produced by
Mycobacterium smegmatis 14468 and is known to have narrow
spectrum activity against M. diemhoferi ATCC 19340 (Saito
et al., 1979). Smegmatocin is not secreted by the bacteria in
the culture supernatant. Therefore to purify smegmatocin, the
cells are ultrasonicated to release the bacteriocin in the culture
supernatant. The smegmatocin is heat labile and inactivated at
100°C; 10 min treatment. It is also inactivated by proteolytic
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enzymes such as pepsin, trypsin and chymotrypsin (Saito et al.,
1979). Further, Saito et al. (1979) also showed that smegmatocin
inhibited the human cell line HeLa S3. Treatment of HeLa S3 cells
with smegmatocin at a concentration of 64 and 128 AU/ml for
96 h caused almost 1 log decrease in the number of viable cells as
compared to control heat-inactivated smegmatocin preparation.
The cancer cells showedmorphological changes, such as shrinking
and appearance of vacuoles in their cytoplasm (Saito et al., 1979).
In another report, treatment of mKS-A TU-7 cells with
as low as 32 AU/ml of smegmatocin for 12 to 24 h led to
significant decrease in the number of cells as compared to normal
untransformed cells. The reduction in the number of cells was
associated with the reduction of both protein and DNA synthesis.
The synthesis of DNA in the transformed cells almost ceased
after 6 h of smegmatocin exposure; whereas in the controls
the synthesis continued (Saito and Watanabe, 1981). In yet
another report, AS-Il cells and HGC-27 cells from metastatic
lymph node of gastric cancer were treated with smegmatocin
14468. The smegmatocin showed dose-dependent lethal effects
on the cancer cell lines. The cells of AS-II were more sensitive
to smegmatocin as compared to HGC-27 cell line (Saito and
Watanabe, 1979). Further investigations are required to determine
the mechanism of action of smegmatocin against human cancer
cell lines because smegmatocin is quite a large protein and its
activity and uptake inside the eukaryotic cell is not known.
Interestingly, live M. smegmatis has shown immunomodulatory
protective effects against mice model of cancer (Young et al.,
2004; Rich et al., 2012), however, the role of smegmatocin in the
cancer mouse model was not studied. Hence it will be interesting
to compare the protective effects of smegmatocin-producing and
non-producingM. smegmatis bacterial cells on the cancer cells, in
vivo.
CONCLUSION AND FUTURE
PERSPECTIVES
Some bacteriocins have shown in vitro cytotoxicity against cancer
cells at nano or micromolar concentrations. The cytotoxicity
of the bacteriocin and its ability to differentially target cancer
cells may depend on its structural properties such as number
of positively charged amino acids, hydrophobicity and ability
to form amphipathic structures or oligomerization as in case
of other antimicrobial peptides (Gaspar et al., 2013). The cell
membrane appears to be the major target of bacteriocins in
eukaryotic cells. The enhanced expression of negatively charged
cell surface molecules on the cancer cells makes them prone to
the cytotoxic activity of the bacteriocins (Zhao et al., 2006). The
mechanisms of cytotoxicity of bacteriocins include induction of
apoptosis and/or depolarisation of the cell membrane leading
to permeability changes. Few of them may induce both necrosis
and apoptosis. The membrane potential measurement studies
have shown that within few seconds of the interaction of
bacteriocin with the sensitive eukaryotic cell, depolarisation of
its surface and increase in its permeability occured leading to the
cell death. The rapid killing induced by cytotoxic bacteriocins
might indicate the non-receptor-mediated mode of action. The
membrane surface glycoproteins and glycosaminoglycans were
shown to be the cancer cell targets at least in case of plnA (Sand
et al., 2013); however, in case of other bacteriocins, such as nisin
A, plnC and pediocin glycosaminoglycans appeared to prevent
the cytotoxic action on the cancer cells (Martín et al., 2015).
Further studies are required to substantiate the role of surface
molecules in their interaction with other cytotoxic bacteriocins.
The anticancer potential of bacteriocins has been tested under
laboratory conditions. However no data is available regarding
their efficacies in cancer patients. The advantages of bacteriocins
as therapeutic agents are that they are small peptides and thus
are mostly non-immunogenic by nature (Bhunia et al., 1990).
Secondly they are biodegradable and easily hydrolysed to simple
amino acids, although this also means that they may not be as
long-lasting. Due to these safety aspects, nisin has been approved
for use as food preservative in more than 50 countries worldwide
and it holds a GRAS (generally regarded as safe) status by WHO
(Deegan et al., 2006). One of the major challenge for the use of
bacteriocins as drugs is to improve the stability of bacteriocins
in human gut or tissues. Efforts have been made to chemically
synthesize bacteriocin peptides incorporating -amino acids that
are less susceptible to proteolytic cleavage in the gut. Analogs
of lactococcin G were synthesized with the N- and C-terminal
residues replaced with -amino acids that were less susceptible to
exopeptidases without much effect on their activities (Oppegård
et al., 2010). In another study, site-directed alteration of trypsin
recognition sites in salivaricin P resulted in trypsin-resistant
variants with only slight variation in its anti-listerial activity (Shea
et al., 2010). Similar studies aimed at enhancing the stability
and potency of anticancer bacteriocins is warranted. Further, the
functional vehicles for the targeted and controlled delivery of
bacteriocins could also improve their in vivo stabilities.
Another hurdle in the commercialisation of therapeutic
bacteriocins is the production and purification of bacteriocins
on a large scale. The bacteriocins are purified from the
culture supernatant by using a combination of cationic and
hydrophobic chromatography and the typical concentrations
of purified bacteriocins are less than a milligram per liter
of the culture (Carolissen-Mackay et al., 1997). However, the
knowledge about the genetic organization and biosynthetic
pathways of various bacteriocins has facilitated the heterologous
production of bacteriocins in different hosts as fusion proteins.
It has simplified the purification protocols and enhanced the
bacteriocin production. The details of heterologous production
of bacteriocins are reviewed earlier (Rodríguez et al., 2003;
Lohans and Vederas, 2012). Further, as bacteriocins are non-
immunogenic, biodegradable and shown to have the cancer cell-
specific toxicities, their potential to serve as synergistic agents
to conventional cancer drugs should also be tested. The stage is
now set where the potential of bacteriocins as anticancer agents
should be harnessed for designing safer and better therapies for
the mankind.
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